D-0127-2024 Class III Terminated

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

FDA drug recall D-0127-2024 was initiated by Teva Pharmaceuticals USA, Inc on Nov 10, 2023 and is designated Class III. Reason for recall: OOS for viscosity The recall status is terminated (terminated Jun 3, 2024).

Recall details

Product Type
Drugs
Report Date
Dec 6, 2023
Initiation Date
Nov 10, 2023
Termination Date
Jun 3, 2024
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Testosterone Gel, 1.62% CIII (Alcohol 80% v/v), packaged in 30 unit-dose packets per carton, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0591-2926-30

Reason for recall

OOS for viscosity

Distribution pattern

USA nationwide

Code information

Lot #: 100029472, Exp. 2/29/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0127-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0127-2024. Report a data issue: hello@regdatalab.com.